1. Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry;Branstetter;RAND J. Econ.,2016
2. Drug competitive intelligence and analytics;Cortellis;Clarivate,2022
3. Innovation in the pharmaceutical industry: New estimates of R&D costs;DiMasi;J. Health Econ.,2016
4. FDA (1998) ‘Guidance for Industry 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act’, (June), pp. 1–9. Available at: 〈https://www.fda.gov/regulatory-information/search-fda-guidance-documents/180-day-generic-drug-exclusivity-under-hatch-waxman-amendments-federal-food-drug-and-cosmetic-act〉 (Accessed: 2 March 2022).
5. FDA (2021) Paragraph IV Drug Product Applications: Generic Drug Patent Challenge Notifications. Available at: 〈https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applications-generic-drug-patent-challenge-notifications〉 (Accessed: 2 March 2022).